Emerging as a significant development in the battle against obesity, the drug is attracting considerable interest . It combines effects of two recognized GLP-1 binding agonists, dulaglutide , with an unique glucose-dependent peptide component. Preliminary clinical data have shown significant weight loss in patients with obesity , possibly offering